The mPancreas is a wearable bio-artificial pancreas that replicates real-time endocrine function, ensuring precise glycemic control for Type 1 Diabetes (T1D) patients. It integrates AI-driven adaptation, biomimetic microfluidic design, and immunoisolated islets, providing continuous insulin and glucagon regulation to prevent hyperglycemia and hypoglycemia.

Unlike traditional treatments, mPancreas eliminates injections, offering minute-to-minute glucose balance via vascular integration with real-time biosensor monitoring. It removes the need for immunosuppressive therapy, overcoming limitations of pancreas and islet transplantation, which remain costly, invasive, and donor dependent. Its compact, patient-friendly design transforms diabetes care, providing seamless metabolic autonomy and a scalable solution for long-term health.

The mPancreas Bio-Artificial Pancreas offers a Wearable biomimetic, scalable solution, restoring real-time physiological glucose regulation, paving the way for a true cure.

At its core, the mPancreas incorporates human islets within a central bioreactor chamber, supported by two patented technologies: the Microfluidic Capillaries and Lymphatics (MCAL) Chipset and Biochipset. These platforms provide precision control of capillary and lymphatic microflow dynamics essential to islet health. It utilizes a patented ELP-PEI (elastin-like polypeptide–polyethyleneimine) surface modification chemistry, enabling islets tethering to the membrane scaffold that improves their viability, preserves three-dimensional structure, and supports sustained hormone release over time.

The biomimetic architecture includes selectively permeable, hemocompatible Polyethersulfone (PES) membranes with appropriate Molecular Weight Cut-Off (MWCO) of 50 kDa, which allow bidirectional exchange of key molecules—glucose, insulin, oxygen, nutrients, and metabolites—while preventing immune cell infiltration. This immunoisolating barrier eliminates the need for immunosuppressive drugs, offering a safer, long-term therapeutic solution.

A core innovation of the mPancreas is its ability to provide true physiologic hormonal counter-regulation. During hyperglycemia, insulin is released to reduce blood glucose; during hypoglycemia, glucagon is secreted to elevate it. This dual-hormone feedback closely mirrors the finely tuned endocrine responses of a healthy pancreas, ensuring continuous glycemic regulation.

Integrated biosensors continuously monitor glucose, oxygen, and lactate levels. These inputs are analyzed by advanced AI-driven algorithms that dynamically adjust hormone output in real time, matching metabolic demand. The intuitive interface provides predictive alerts and data visualization, empowering patients and clinicians with proactive control.

The device connects to the patient’s vasculature via tunneled central line catheters, enabling continuous perfusion of oxygenated blood to the islet bioreactor. Its compact, wearable form allows for full mobility and independent living, liberating patients from the constraints of insulin pumps and injection regimens.

Safety and longevity are enhanced by zwitterionic modifications that reduce biofouling and improve hemocompatibility, resulting in longer function, avoid clotting.

Key Benefits

• Real-time physiologic insulin and glucagon delivery for precise glycemic control
• No immunosuppression needed due to immunoisolating PES membranes
• Continuous biosensor monitoring of glucose, oxygen, and lactate
• AI-adaptive hormonal control with predictive safety alerts
• Patented MCAL and Biochipset technologies for optimized flow dynamics
• ELP-PEI surface chemistry for islet tethering and functional enhancement
• Fully wearable and mobile design for untethered living
• Zwitterionic coatings reduce fouling and increase durability

The mPancreas is a paradigm shift in diabetes care—a physiologically intelligent, AI-enhanced, clinically scalable bioartificial pancreas system.